About this trial
This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
English speaking adults aged 18 and above
Diagnosed with DSM-5 cannabis use disorder, severe
Disqualifiers
Active psychosis, active suicidality or homicidality or any psychiatric condition that impair ability to provide informed consent
Any current or lifetime diagnosis of eating disorders including anorexia, bulimia, binge eating or
Comorbid substance use disorder
BMI<21 kg/m2
Trial design
Crossover
Treatments tested in this trial
Tirzepatide
Drug2.5mg subcutaneous injection once
Placebo
DrugSaline placebo subcutaneous injection once
Treatment groups
Trial outcomes
Primary outcomes
Cue-Induced Craving
Craving scores will be assessed using a cue-reactivity paradigm in which participants are exposed to cannabis\]-related cues. Scores range from 0 to 30, with higher scores indicating greater craving intensity.
Secondary outcomes
Serious adverse event
Incidence of serious adverse events
Cravings
Cannabis craving scale using the 12-item questionnaire, each item scored on a 1-7 sale. Higher scores (either average or summed) indicates stronger cravings.
Abstinence
Percent days abstinent from cannabis
Weight
Weight
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: